-
Mashup Score: 0
Upper Tract Urothelial Cancer (UTUC), Circulating tumor DNA (ctDNA), Circulating Tumour DNA in Plasma Is Feasible and May Be a Potential Biomarker, detection of tumor-specific mutations.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 12
PADUA Renal (SPARE) Nephrometry Scoring System, Renal Function Outcomes After Robot-Assisted Partial Nephrectomy, Robot-Assisted Partial Nephrectomy, UroCCR Study 93, Chronic Kidney Disease (CKD), RAPN for cT1a-b stage tumors, Chronic Kidney Disease (CKD), SPARE trial, RENAL score, PADUA score.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1Active Surveillance Should Not Be Routinely Considered in ISUP Grade Group 2 Prostate Cancer - Beyond the Abstract - 14 hour(s) ago
prostate cancer, grade group 2 prostate cancer, ProtecT trial, International Society of Urological Pathologists (ISUP), ISUP grading system, radical prostatectomy, low-grade prostate cancer.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0PSMA-Targeted Radionuclide Therapy in the Pre- and Post-Chemotherapy Settings in Prostate Cancer - Louise Emmett - 15 hour(s) ago
In a conversation with Phillip Koo, Louise Emmett unpacks the complexities of PSMA-targeted diagnostics and treatments in prostate cancer. They explore the significance of key trials such as ENZA-p, VISION, TheraP, PSMAfore, SPLASH, and ECLIPSE, examining the challenges in proving overall survival benefits and the potential of adaptive dosing strategies for improved patient outcomes. Emmett…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 10
At the 2024 PSMA Conference PSMA PET and RLT: Present and Future, Louise Emmett explores enhancing prostate cancer diagnosis with PSMA PET imaging, revealing the PRIMARY trials’ findings that combining PSMA PET with MRI significantly improves the accuracy of detecting clinically significant malignancies. Dr. Emmett introduces the PRIMARY score for interpreting PSMA PET results and discusses…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0
testicular cancer, Testicular germ cell tumors (TGCTs), non-seminomatous germ cell tumors (NSGCTs), retroperitoneal lymph node dissection (RPLND), non-seminomatous germ cell tumors after chemotherapy.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 7An Analysis in NMIBC Patients - A Comparative Study of White Light and Blue Light Cystoscopy in an Equal Access Setting - Stephen B. Williams - 18 hour(s) ago
Stephen Williams discusses the evolving role of blue light cystoscopy in detecting non-muscle invasive bladder cancer (NMIBC). The conversation covers its pathophysiology, diagnostic and surveillance applications, emphasizing selective utilization and benefits post-BCG therapy. Dr. Williams references a study in Clinical Genitourinary Cancer, sharing insights from a study comparing blue and…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1Case-Based Discussion on Navigating the Evolving Landscape of Castrate-Resistant Prostate Cancer Management - Oliver Sartor - 19 hour(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: A. Oliver Sartor, MD, Professor of Medicine, Urology, and Radiology, Director Radiopharmaceutical Trials, Mayo Clinic, Rochester, MN Rana McKay, MD , Medical Oncologist, Associate Professor of…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 4Radioligand Therapy's Role in Treating mCRPC - Oliver Sartor - 19 hour(s) ago
Alicia Morgans engages in a conversation with Oliver Sartor about the evolving landscape of Radioligand Therapy in metastatic castration-resistant prostate cancer (mCRPC). Dr. Sartor discusses the trials in progress for each PSMAfore, SPLASH, and ECLIPSE trials. Dr. Sartor notes the trials are not complete and with little to no data the treatments are not yet ready for widespread clinical…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1Patient Selection for PSMA Radioligand Therapy - Ephraim Parent - 20 hour(s) ago
Phillip Koo engages in a conversation with Ephraim Parent on the pivotal role of PSMA PET imaging in selecting patients for radioligand therapy (RLT). Dr. Parent emphasizes the critical importance of accurately identifying patients through PSMA PET imaging to ensure successful outcomes with Pluvicto therapy. He outlines the standardized practice of evaluating patients with PSMA PET to detect…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Join @PhillipKooMD and @EphraimParent in a deep dive into the power of PSMA PET imaging for guiding radioligand therapy decisions underscoring the crucial role of precise patient selection and leveraging established criteria like the PROMISE guidelines > https://t.co/QrRCmWSiOM https://t.co/dA0D6QaFOt
-
Patient-specific targeted analysis of circulating tumor DNA in plasma is feasible and may be a potential biomarker in upper tract urothelial cancer. #BeyondTheAbstract on UroToday > https://t.co/erLUhZktTU @wjurol https://t.co/LhezyLLNYp